Overview

Tolerability, Safety and Efficacy of SAD448 in Subjects With Ocular Hypertension

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the tolerability and safety of SAD448 and explore the compound's effect on intraocular pressure in subjects with ocular hypertension.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis
Criteria
Key inclusion criteria:

- Males and females, 18 - 65 years of age, with ocular hypertension

- Females must be post-menopausal or surgically sterile

Key exclusion criteria:

- Diagnosis of glaucoma in either eye

- A history of or current eye conditions or medical problems that would prohibit the use
of an investigational drug